WHAT THE HUMAN DATA SAY
Evidence before enthusiasm.
Some stem-cell therapies are established for narrow medical uses, while most longevity, joint, neurologic and intravenous exosome offerings lack high-quality evidence or approval.
This grade reflects clinically meaningful human evidence for the use described here. It is not a score for popularity, mechanism, animal lifespan results or the number of products already being sold.
HOW IT FITS
A practical role—without pretending it is universal.
Verify the exact product, regulatory status, trial registration, manufacturing standards and indication. Prefer an academic or regulated clinical pathway over a tourism package.
TRACK WHAT MATTERS
Know whether it is creating value.
Exact product and cell source
Regulatory and trial identifiers
Condition-specific objective outcomes
SAFETY & BOUNDARIES
What should make you pause.
- Risks include infection, immune reactions, clots, abnormal tissue growth and financial exploitation.
- The FDA has warned consumers about unapproved regenerative products.
BOOK CONNECTIONS
Where this idea enters the longevity conversation.
Book inclusion explains why the idea is culturally important; the evidence grade above determines how strongly The Modern Bio treats the claim.